KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program.

Gary R Lichtenstein, Jessica R Allegretti, Edward V Loftus, Peter M Irving, Rupa Banerjee, Aline Charabaty, Tanja Kuehbacher, Eustratios Bananis, John C Woolcott, Alexis B Dalam, Krisztina Lazin, Michael Keating, Aoibhinn McDonnell, Silvio Danese

Inflamm Bowel Dis 31(9) 2352-2362

PMID40184206
PMCIDPMC12455601
DOI10.1093/ibd/izae308
发表日期2025-04-04
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。
摘要

摘要

BACKGROUND: Patient age can impact the safety and efficacy of ulcerative colitis (UC) treatments. Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. Here, we evaluate the impact of age on etrasimod safety and efficacy in patients with UC in the phase 3 ELEVATE UC clinical program. METHODS: Data were pooled from ELEVATE UC 52 and ELEVATE UC 12 in patients receiving etrasimod 2 mg QD or placebo. Proportions and incidence rates (IRs) per 100 patient-years of treatment-emergent adverse events (AEs) were stratified by age (<40, 40-59, and ≥60 years). With the same age stratifications, efficacy was evaluated in patients with baseline Modified Mayo scores of 5-9 and 4-9 for the primary efficacy endpoint (clinical remission) and secondary efficacy endpoints. RESULTS: Overall, 787 patients were enrolled (<40 years, n = 420 [53.4%]; 40-59 years, n = 276 [35.1%]; and ≥60 years, n = 91 [11.6%]). Arthralgia, fatigue, and hypertension IRs were higher in older patients, irrespective of treatment. Serious AEs and AEs leading to treatment discontinuation were low and consistent across age groups. Significantly more patients receiving etrasimod 2 mg QD vs placebo achieved efficacy endpoints, regardless of age. CONCLUSIONS: The safety profile of etrasimod 2 mg QD in the ELEVATE UC population was consistent across age groups, with no change in the incidence of AEs. Patients receiving etrasimod vs placebo showed significant clinical benefit, regardless of age. CLINICALTRIALS.GOV: NCT03945188; NCT03996369.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Proportions of (A) SAEs and (B) TEAEs leading to discontinuation reported in the ELEVATE UC clinical program, stratified by age (Pivotal UC cohort [Pivotal UC cohort comprised placebo-controlled phase 3 trials, ELEVATE UC 52 (NCT03945188) and ELEVATE UC 12 (NCT03996369)] SAS with baseline MMS 4-9). Incidence rates were calculated as n /PY adjusted to per 100 PY, where PY is the sum of patients’ time from baseline to first adverse event episode or time in the study if the patient was event-free. 95% CIs for IRs were estimated using a normal approximation to the Poisson model, adjusted per 100 PY. Abbreviations: CI, confidence interval; IR, incidence rate; MMS, modified Mayo score; NC, non-calculable; PY, patient-years; QD, once daily; SAE, serious adverse event; SAS, safety analysis set; TEAE, treatment-emergent adverse event; UC, ulcerative colitis.
非 KM Figure
Figure 2Figure 2. The proportion of patients achieving clinical remission at week 12 (pooled) and week 52 (ELEVATE UC 52) in the ELEVATE UC clinical program, stratified by age (FAS with baseline MMS 5-9). * P < .05, ** P < .01, *** P < .001. Abbreviations: Δ, adjusted difference from placebo; CI, confidence interval; FAS, full analysis set; MMS, modified Mayo score; n , number of responders; N , number of patients in FAS; QD, once daily; UC, ulcerative colitis.
非 KM Figure
Figure 3Figure 3. The proportion of patients achieving (A) clinical response, (B) endoscopic improvement at week 12 (pooled) and week 52 (ELEVATE UC 52), and (C) corticosteroid-free clinical remission at week 52 (ELEVATE UC 52) in the ELEVATE UC clinical program, stratified by age (FAS with baseline MMS 5-9). * P < .05, ** P < .01, *** P < .001. Abbreviations: Δ, adjusted difference from placebo; CI, confidence interval; FAS, full analysis set; MMS, modified Mayo score; n , number of patients meeting each endpoint; N , number of patients in FAS; QD, once daily; UC, ulcerative colitis.
非 KM Figure